Organisation paid for research Program year 2025 Source: CMS Open Payments

Anaheim Clinical Trials

Neither a doctor nor a teaching hospital

Research payments

$15,473,205

538 payments

Through program year 2025, Anaheim Clinical Trials is reported as receiving $15,473,205 in research payments, across 538 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $892,078 13
2024 Research $818,679 17
2023 Research $3,020,815 20
2022 Research $796,262 14
2021 Research $3,873,928 64
2020 Research $1,583,044 104
2019 Research $4,488,399 306

Breakdown

Who paid Research payments · program years 2019–2025
  1. Vertex Pharmaceuticals Incorporated $4,548,146 15 payments
  2. AbbVie, Inc. $1,651,843 33 payments
  3. Biogen, Inc. $1,229,126 2 payments
  4. CSL Behring $992,406 24 payments
  5. Amgen Inc. $939,403 22 payments
  6. Celgene Corporation $798,158 2 payments
  7. Novo Nordisk AS $782,145 317 payments
  8. Merck Sharp & Dohme Corporation $755,861 6 payments
  9. Ucb SA $603,331 15 payments
  10. AstraZeneca UK Limited $578,751 3 payments
Studies the money was for Research payments · program years 2019–2025
  1. A Phase 3, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of VX-548 for Acute Pain After a Bunionectomy $2,696,348 3 payments
  2. M16-856 $1,512,582 19 payments
  3. A Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BIIB133 (Dapirolizumab Pegol) in Healthy Japanese and Caucasian Participants $1,229,126 2 payments
  4. A 2-Part, Phase 1, Single Center, Open-label, Single Ascending Dose Study to Investigate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Subcutaneous and Intravenous CSL312 in Healthy Adult Japanese and Caucasian Subjects $992,406 24 payments
  5. A Phase 1, Randomized, Open-Label, Single-Dose Study to Evaluate the Pharmacokinetics of CC-93538 in Healthy Japanese and Caucasian Adult Subjects (CC-93538-CP-001) $797,575 1 payment
  6. A Dose-ranging Study to Evaluate Efficacy and Safety of VX-150 in Subjects With Acute Pain Following Bunionectomy $717,562 1 payment
  7. A Phase 2, Randomized, Double-blind, Placebo-controlled, Dose-ranging Study Evaluating the Efficacy and Safety of VX-548 for Acute Pain After a Bunionectomy $691,252 3 payments
  8. A placebo-controlled, double-blind, randomized study to assess the safety, tolerability, and pharmacokinetics of Staccato Alprazolam In healthy Japanese, Chinese, and caucasian Participants $603,331 15 payments
  9. A Phase I, Open-label, Randomized, Single-dose Study of Acalabrutinib in Healthy Subjects to Evaluate the Effect of Proton-pump Inhibitor (Rabeprazole) on Acalabrutinib Capsule when Administered Orally with COCA-COLA $578,349 2 payments
  10. A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease $569,713 5 payments
What the money was spent on Research payments · program years 2019–2025
  1. Other $561,629 13 payments

Only reported on some payments, and a payment can report more than one category, so these amounts overlap.

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record